Brief: Oncozenge Receives Conditional Acceptance For Clinical Phase III Trial
28/04/2026 14:38
April 28 (Reuters) - Oncozenge AB ONCOZ.ST: ONCOZENGE RECEIVES CONDITIONAL ACCEPTANCE FOR THE CLINICAL PHASE III TRIAL (‘BEAM-PAIN’) OF BUPIZENGE™ FROM EUROPEAN AUTHORITIES DENMARK ACTS AS REFERENCE MEMBER STATE FOR BUPIZENGETM PHASE III TRIAL OBJECTIVE REMAINS TO ENROL FIRST PATIENT IN Q2 2026 NOW EXPECTS FULL APPROVAL AROUND MID-MAY Source text: ID:nMFNTkqQj Further company coverage: ONCOZ.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))